Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-LUNG01)
DS1062-A-U301: PHASE 3 RANDOMIZED STUDY OF DS-1062A VERSUS DOCETAXEL IN PREVIOUSLY TREATED ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WITHOUT ACTIONABLE GENOMIC ALTERATIONS (TROPION-LUNG01)
-
Clinical Trial Information
Trial Contact: Britton, David ; Thomas, Andrea L
Trial Phone: 321.841.2684 ; 321.841.8284
-
IRB No: W20203580
Protocol Abbrev: TRIO DS1062-A-U301
Principal Investigator: Tirrell Tremayne Johnson, MD
Phase: Drug: Phase III
Age Group: Adult
Secondary Protocol No: TROPION-LUNG01
Treatment: DS-1062a vs Docetaxel
Therapies Involved: Medication
ClinicalTrials.gov ID: NCT04656652
-
Objective
This study will evaluate the efficacy, safety, and pharmacokinetics of DS-1062a versus docetaxel in participants with previously treated advanced or metastatic non-small cell lung cancer (NSCLC) without actionable genomic alterations.
-
Key Eligibility
Adults ≥18 years (if the legal age of consent is >18 years old, then follow local regulatory requirements)
Life expectancy ≥3 months
Has pathologically documented NSCLC that:
-Has stage IIIB, IIIC, or stage IV NSCLC disease at the time of randomization (based on the American Joint Committee on Cancer, Eighth Edition)
-Has documented negative test results for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK)
-Has no known genomic alterations in ROS proto-oncogene 1 (ROS1), neurotrophic tyrosine receptor kinase (NTRK), proto oncogene B-raf (BRAF), or other actionable driver oncogenes with approved therapies (actionable genomic alteration)
